Evaluating patient-reported outcome measures (PROMs) for future clinical trials in adult patients with optic neuritis

被引:3
作者
Panthagani, Jesse [1 ]
O'Donovan, Charles [2 ]
Aiyegbusi, Olalekan Lee [3 ,4 ]
Liu, Xiaoxuan [5 ]
Bayliss, Susan [6 ]
Calvert, Melanie [7 ,8 ]
Pesudovs, Konrad [9 ]
Denniston, Alastair K. [10 ]
Moore, David J. [6 ]
Braithwaite, Tasanee [11 ,12 ]
机构
[1] Univ Hosp Birmingham, Birmingham, England
[2] Kings Coll London, Sch Immunol & Microbiol, London, England
[3] Univ Birmingham, Ctr Patient Reported Outcomes Res CPROR, NIHR Birmingham Biomed Res Ctr, Birmingham Hlth Partners Regulatory Sci & Innovat,, Birmingham B15 2TT, England
[4] Univ Birmingham, NIHR Birmingham Oxford Blood & Transplant Res Unit, Birmingham B15 2TT, England
[5] Univ Birmingham, Univ Hosp Birmingham, Inst Inflammat & Ageing, Hlth Data Res UK, London, England
[6] Univ Birmingham, Inst Appl Hlth Res, Birmingham, England
[7] Univ Birmingham, Inst Appl Hlth Res, Ctr Patient Reported Outcomes Res CPROR, Birmingham Biomed Res Ctr, Birmingham B15 2TT, Warwickshire, England
[8] Univ Birmingham, NIHR Birmingham Oxford Blood & Transplant Res Unit, Birmingham B15 2TT, England
[9] Univ New South Wales, Kensington, NSW, Australia
[10] Univ Birmingham, Univ Hosp Birmingham, Inst Inflammat & Ageing, Inst Appl Hlth Res,Birmingham Hth Partners Regulat, London, England
[11] Kings Coll London, Sch Immunol & Microbiol, London, England
[12] Guys & St ThomasHospital NHS Fdn Trust, Med Eye Unit, London, England
基金
英国科研创新办公室; “创新英国”项目; 澳大利亚研究理事会;
关键词
VISUAL FUNCTION QUESTIONNAIRE; QUALITY-OF-LIFE; MULTIPLE-SCLEROSIS; PLACEBO; SURGERY; VALIDATION; EXPERIENCE; PHASE-3; VISION; IMPACT;
D O I
10.1038/s41433-023-02478-z
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
ObjectiveTo search for and critically appraise the psychometric quality of patient-reported outcome measures (PROMs) developed or validated in optic neuritis, in order to support high-quality research and care.MethodsWe systematically searched MEDLINE(Ovid), Embase(Ovid), PsycINFO(Ovid) and CINAHLPlus(EBSCO), and additional grey literature to November 2021, to identify PROM development or validation studies applicable to optic neuritis associated with any systemic or neurologic disease in adults. We included instruments developed using classic test theory or Rasch analysis approaches. We used established quality criteria to assess content development, validity, reliability, and responsiveness, grading multiple domains from A (high quality) to C (low quality).ResultsFrom 3142 screened abstracts we identified five PROM instruments potentially applicable to optic neuritis: three differing versions of the National Eye Institute (NEI)-Visual Function Questionnaire (VFQ): the 51-item VFQ; the 25-item VFQ and a 10-item neuro-ophthalmology supplement; and the Impact of Visual Impairment Scale (IVIS), a constituent of the Multiple Sclerosis Quality of Life Inventory (MSQLI) handbook, derived from the Functional Assessment of Multiple Sclerosis (FAMS). Psychometric appraisal revealed the NEI-VFQ-51 and 10-item neuro module had some relevant content development but weak psychometric development, and the FAMS had stronger psychometric development using Rasch Analysis, but was only somewhat relevant to optic neuritis. We identified no content or psychometric development for IVIS.ConclusionThere is unmet need for a PROM with strong content and psychometric development applicable to optic neuritis for use in virtual care pathways and clinical trials to support drug marketing authorisation.
引用
收藏
页码:3097 / 3107
页数:11
相关论文
共 77 条
[1]  
Administration FD, 2020, PAT FOC DRUG DEV GUI
[2]  
Administration USFaD, 2020, FDA PAT FOC DRUG DEV
[3]  
Alliance JL, 2013, SIGHT LOSS VISION PR
[4]   Patient-reported outcomes in the spotlight [J].
不详 .
LANCET NEUROLOGY, 2019, 18 (11) :981-981
[5]   Visual function more than 10 years after optic neuritis: Experience of the optic neuritis treatment trial [J].
Beck, RW ;
Gal, RL ;
Bhatti, MT ;
Brodsky, MC ;
Buckley, EG ;
Chrousos, GA ;
Corbett, J ;
Eggenberger, E ;
Goodwin, JA ;
Katz, B ;
Kaufman, DI ;
Keltner, JL ;
Kupersmith, MJ ;
Miller, NR ;
Moke, PS ;
Nazarian, S ;
Orengo-Nania, S ;
Savino, PJ ;
Shults, WT ;
Smith, CH ;
Trobe, JD ;
Wall, M ;
Xing, DY .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 2004, 137 (01) :77-83
[6]  
BOURQUE LB, 1986, ARCH OPHTHALMOL-CHIC, V104, P356
[7]   The effectiveness of providing peer benchmarked feedback to hip replacement surgeons based on patient-reported outcome measures-results from the PROFILE (Patient-Reported Outcomes: Feedback Interpretation and Learning Experiment) trial: a cluster randomised controlled study [J].
Boyce, Maria B. ;
Browne, John P. .
BMJ OPEN, 2015, 5 (07)
[8]   Trends in Optic Neuritis Incidence and Prevalence in the UK and Association With Systemic and Neurologic Disease [J].
Braithwaite, Tasanee ;
Subramanian, Anuradhaa ;
Petzold, Axel ;
Galloway, James ;
Adderley, Nicola J. ;
Mollan, Susan P. ;
Plant, Gordon T. ;
Nirantharakumar, Krishnarajah ;
Denniston, Alastair K. .
JAMA NEUROLOGY, 2020, 77 (12) :1514-1523
[9]   Vision Loss from Atypical Optic Neuritis: Patient and Physician Perspectives [J].
Braithwaite, Tasanee ;
Wiegerinck, Nils ;
Petzold, Axel ;
Denniston, Alastair .
OPHTHALMOLOGY AND THERAPY, 2020, 9 (02) :215-220
[10]   Cochrane corner: why we still don't know whether anti-TNF biologic therapies impact uveitic macular oedema [J].
Braithwaite, Tasanee ;
Davis, Nicki ;
Galloway, James .
EYE, 2019, 33 (12) :1830-1832